As a senior executive with extensive international expertise in the pharmaceutical and biotech industry, Koen Wiedhaup is actively involved in the creation of new life sciences companies. Over the last fifteen years, he has worked together with UK and USA based venture capital firms and has served as a board member of governmental foundations, such as the Netherlands Genomics Initiative and Health Valley Netherlands. He is a member of the Supervisory Board of the BioGeneration Ventures Fund I, and of the Investment Committee of PPM Oost, a venture capital company managing regional and national government funding in the Netherlands. Wiedhaup has been, or still is, a member of supervisory and advisory boards of thirteen life sciences companies in the USA and Europe, several of which have successfully completed an IPO. Over the last decade, he has been active as vice-president of the Supervisory Board of the University Medical Center in Maastricht (AZM) and as member of the Supervisory Board of the Canisius-Wilhelmina Hospital in Nijmegen. He is a member of the Ambassadors Network of the Dutch University of Twente. From 1977 to 1994, Wiedhaup has been board member and managing director for Global R&D of the former pharmaceutical company Organon, and subsequently Group Director of Akzo-Nobel Pharma, responsible for R&D and strategic planning until 2000. Koen Wiedhaup obtained his PhD at the University of Amsterdam. Previous to joining Organon, he held positions at the San Francisco Medical Center of the University of California, at Stanford University, CA, and with Unilever in Rotterdam and London.